Leading the Way in Life Science Technologies

GEN Exclusives

More »

GEN News Highlights

More »
Nov 17, 2008

Midatech Forms Nanotech-Focused Subsidiary

  • Midatech Group has formed a new drug development subsidiary, PharMida. Formation of this Basel-based unit follows an investment by a group of Switzerland-based private investors into Midatech. PharMida will be headed by Fritz R. Buhler, M.D., as chairman and Jan Mous, Ph.D., as CEO.

    The mandate of PharMida is to develop a strong portfolio of clinically validated gold nanoparticle-drug combinations. Furthermore, PharMida will manage in-house drug development, commercial partnerships, and out-licensing opportunities in order to leverage a collection of already existing and promising Midatech products or product lines.



Be sure to take the GEN Poll

Scientifically Studying Ecstasy

MDMA (commonly known as the empathogen “ecstasy”) is classified as a Schedule 1 drug, which is reserved for compounds with no accepted medical use and a high abuse potential. Two researchers from Stanford, however, call for a rigorous scientific exploration of MDMA's effects to identify precisely how the drug works, the data from which could be used to develop therapeutic compounds.

Do you agree that ecstasy should be studied for its potential therapeutic benefits?

More »